Early biotech IP is often illiquid by default. The experiments that de-risk a platform sit inside private labs, and the intellectual property they generate is hard to value before there is a clear readout. Traditional venture rounds can force large, dilutive raises long before the science is ready, a dynamic that works against both researchers and the capital that backs them.
The IP-NFT model is one structured response: a defined piece of research IP is represented on-chain, so ownership, terms, and coordination can be legible rather than buried in opaque contracts. Fractional ownership pools and IPTs can give institutional participants a measured position in early science with a different liquidity and time-horizon profile than a single private stake, without turning the corporate site into a token promotion.
Artan Bio and the VitaRNA community sit on opposite sides of a deliberate separation: the biotech company tells the science story; the community layer handles token participation and DeSci alignment. For institutions evaluating the framework, the question is not whether early IP can be funded. It is whether it can be funded with clearer terms, earlier liquidity, and less dilution than the default path.
This is educational context, not investment advice.